The new capital will accelerate investments in startups with a clear path to elevating health outcomes on a global scale

SpringTide Ventures, a leader in early-stage HealthTech venture capital, today announced the successful close of its Fund II at $65 million, bringing its total assets under management to over $100 million. This new fund underscores the firm’s continued commitment to driving innovation and elevating health globally through investments in digital health, medical devices, life sciences, and tech-enabled care delivery.

"Fund II presents an exciting opportunity to deepen our impact on human health by partnering with entrepreneurs who are positively disrupting healthcare," said Austin Walters, Managing Partner at SpringTide Ventures. “This milestone is not just a reflection of our past successes but a testament to the commitment of our team, partners and founders to bring transformative solutions to market that enhance patient care, improve outcomes, and expand access to quality care."

Noteworthy achievements from SpringTide Ventures’ portfolio include:

• GreatExpectations.io: The world’s leading data quality tooling company recently surpassed a rate of over 15 million downloads per month.
• Pathology Watch: An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million.
• Debut Biotech: A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal.
• OpenLoop: An end-to-end telemedicine enablement company surpassed $100 million in annualized revenues in early 2024.

"We are so proud of the extraordinary achievements of our current founders and partners and are inspired by their commitment to grow and scale," added Walters. "As we venture into this new chapter, our resolve is stronger than ever to support entrepreneurs in challenging the status quo and bringing life-changing technologies directly to those who need them most."

SpringTide Ventures strategically aligns its investments by engaging with industry experts and insiders to identify key trends and untapped opportunities. The firm then proactively seeks out founders and entrepreneurs at the forefront of healthcare innovation, particularly those harnessing advanced technologies to address pressing challenges. Technologies such as artificial intelligence, next-generation sequencing, and flexible electronics are leveraged to create solutions that enhance patient care, improve health outcomes, and broaden access to quality healthcare services. This refined approach ensures that SpringTide Ventures contributes to the advancement of healthcare and supports the growth of businesses poised to make a significant impact in the industry.

For more information about SpringTide Ventures, visit: https://springtide.com/.

About SpringTide Ventures

SpringTide Ventures is an investment firm dedicated to supporting the world’s best healthcare innovators. Based in Boston, Salt Lake City, and San Francisco, the firm currently has $100 million in total assets under management, focusing on early-stage investments in digital health, medical devices, life sciences, and tech-enabled care delivery. For more information, visit https://springtide.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417417817/en/